ADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) announced that Ameet Mallik, CEO, will participate in a fireside chat at Morgan Stanley’s 20th Annual Global Healthcare Conference on September 13, 2022, at 11:45 a.m. ET. A live webcast will be available on the Investors section of the company’s website, with a replay accessible for 30 days.

ADC Therapeutics is focused on developing innovative antibody drug conjugates to treat cancer, including ZYNLONTA, which targets relapsed or refractory diffuse large B-cell lymphoma.

LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley’s 20^th Annual Global Healthcare Conference on Tuesday, September 13^th at 11:45 a.m. ET.

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA^® is a registered trademark of ADC Therapeutics SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005337/en/

Investors



Eugenia Litz

ADC Therapeutics

Eugenia.Litz@adctherapeutics.com

+44 7879 627205



Amanda Hamilton

ADC Therapeutics

amanda.hamilton@adctherapeutics.com

+1 917-288-7023



Media



Mary Ann Ondish

ADC Therapeutics

maryann.ondish@adctherapeutics.com

+1 914-552-4625

Source: ADC Therapeutics

FAQ

When will ADC Therapeutics participate in the Morgan Stanley Global Healthcare Conference?

ADC Therapeutics will participate in the Morgan Stanley’s 20th Annual Global Healthcare Conference on September 13, 2022.

Who is the CEO of ADC Therapeutics participating in the conference?

Ameet Mallik is the CEO of ADC Therapeutics who will participate in the conference.

What time will the ADC Therapeutics fireside chat take place?

The fireside chat will take place at 11:45 a.m. ET.

Where can I watch the ADC Therapeutics conference presentation?

The presentation can be watched live on the Investors section of ADC Therapeutics' website.

What is ZYNLONTA and how is it related to ADC Therapeutics?

ZYNLONTA is an FDA-approved treatment by ADC Therapeutics for relapsed or refractory diffuse large B-cell lymphoma.